Candidates are able to view their GPAT 2018 qualifying status, Ranks Secured, score obtained in each section and the aggregate marks. They are advised to download and print GPAT result 2018 and score card for future references.

Admission open M.Pharm 2018- 2019 , M.Tech 2018 at BHU Varanasi

1. Requirement of Aadhaar for the Applicants2.Following is required to fillup the online application form:Aadhaar Number or other Id Number (as detailed in Section 1 above)E-mail ID for registration and for receiving all future correspondence till the admission process is over and subsequently, if admitted.Mobile Number (in use) to receive SMS based notifications/communications related to the online application, Admit card, Entrance Test Result, Admission Counseling etc till the admission process is over and subsequently, if admitted.Recent passport size colour photograph (for scanning and uploading in “jpeg” format only. File size of scanned photograph should not be more than 100KB).Your signature using Blue/Black pen on white sheet (for scanning and uploading in “jpeg” format only. File size of scanned signature should not be more than 100KB).Access to an online payment facility / service such as:Net BankingCredit cardATM-cum-Debit card

3. Online Application Process 3.1: Registration on the Portal [www.bhuonline.in]-Step 1: Please click on “Apply for Admission” button given on the home page of the BHU Entrance Test Portal Step 2: On clicking the link, you will be directed to a new page having an Applicant Login Box. Below the login fields there is a link “Register Yourself”. Please click on this link.Step 3: When you click the link you will be shown a Registration Form asking for various details. Fields for information marked with “Red coloured bullets” are to be essentially filled up. These fields cannot be left blank. Once you fill the details, you can click on the “Sign up” button at the bottom for completing the registration process.Step 4: Activation and validation of Registration

Step 1: After successful registration on the Portal [www.bhuonline.in], you are required to login, fill up the Authentication Form giving particulars for authentication of your identification.3.2: Authentication of Candidate’s identity

Aurobindo Pharma gets USFDA nod for Fondaparinux Sodium Injection

Aurobindo Pharma gets USFDA nod for Fondaparinux Sodium injection

Aurobindo Pharma has recently received final approval from US Food &amp; Drug Administration(USFDA) to manufacture and market its generic version of Fondaparinux Sodium injection. Theproduct is approved in multiple strengths including 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6mL, and 10mg/0.8mL single-dose prefilled syringes.

The product is approved based on its bioequivalence and therapeutic equivalence to the referencelisted drug product Arixtra Injection, a registered trademark of Mylan Ireland.

The product is indicated for prevention and treatment of deep vein thrombosis. It is the 52nd approved ANDA (including 2 tentative approvals) from Unit IV formulation facility based at Hyderabad, India for manufacturing general injectable and ophthalmic products. To date the company has a total of 350 ANDA approvals (313 final approvals, including 17 from Aurolife Pharma LLC, and 37 tentative approvals) from USFDA. The approved product has an estimated market size of USD 73 million for the 12 months ended October 2017.

The product is expected to be launched by late January 2018 or early February.

Lupin launched generic Vibra-Tabs® Tablet in the United States

Lupin launched generic Vibra-Tabs® Tablet in the US

Reported by: Shikha Jain

Lupin Pharmaceuticals, Inc., has successfully launched Doxycycline Hyclate Tablet USP, 100mg in United States dated 19 January 2018. The product is approved by USFDA on 11September 2017. It is a generic equivalent of Pfizer Inc.’s Vibra-Tabs®, 100 mg, indicated fortreatment of several microbial infections and as an adjunctive therapy in certain acne.According to IMS MAT November 2017, Doxycycline Hyclate Tablet USP, 100 mg had annualsales of approximately USD 144 million in the US.

On 19 December 2017, AuroMedics Pharma LLC has voluntarily recalled one lot (CPO170035,EXP. May 2019) of Pantoprazole Sodium for Injection 40 mg per vial as a result of presence ofglass particles in the vial. The product has commenced distribution since 7 August 2017. Theissue was highlighted from one of the received market complaint where the contents of one vialwere found to contain a piece of glass.

The intravenous administration of a glass particulate may result in local irritation or swelling orlife-threatening consequences like blockage and clotting in blood vessels. However ,to date, noany adverse events are attributed to this recall.

The product can be identified as ‘vial stoppered with grey slotted rubber stopper and sealed withaluminum seals having Sky Blue color polypropylene disc and is packaged in a carton containing10 vials, NDC: 55150-202- 10.

Consumers/ distributors/ retailers that have the recalled lot should immediately stop using andreturn to place of purchase/contact their doctor as appropriate.

FDA approves angiotensin II (Giapreza) to treat hypotension in adults with septic or other distributive shock

FDA approves drug to treat hypotension in adults with septic or other distributive shock

Reported by Shikha Jain

On 21 December 2017, The U.S. Food and Drug Administration today granted approval of intravenous injection of angiotensin II (Giapreza) to La Jolla Pharmaceutical Company to increase blood pressure in adults with septic for other distributive shock. Shock is a critical condition in which blood pressure drops to extremely low level that the vital organs like brain, kidneys etc can’t maintain blood flow to function properly and thus can result in organ failure and even death. Therefore there is a dire need of treatment options for critically ill hypotensive patients who do not adequately respond to existing therapies.

In this context, Giapreza effectively increases blood pressure when added to conventional treatments of hypotension. However, it can cause dangerous blood clots with serious consequences (e.g. deep venous thrombosis) and therefore it is advised to use prophylactic treatment for blood clots.

M.Sc. Biotech with Microbiology as one semester paper (Fresher or Experienced)M.Sc. Microbiology (Fresher or Experienced)B. Pharm/ M. Pharm with Microbiology as one semester paper (Fresher or Experienced)

Minimum CGPA/Percentage Required:

CGPA: 6.85 and above on a scale of 10Percentage: 65% and above

Program Fee:Biocon Academy is an Advanced Learning Educational Initiative which takes forward our commitment to affordability and greater access. The BITS-Biocon Certificate Program Applied Industrial Microbiology is being made available to students at a 40% cost, of the program.

The Biocon Merit Scholarship to all students selected through a rigorous process, will enable students to pursue this one-of-its kind program at an affordable cost.

Biocon Scholarship60% Of the cost of the Program to all selected students.

CCMB Summer Training Program - 2018
Eligibility Qualifications
The training program is open to students from all branches of sciences and open to all
Indian Universities/Research Institutes.
M.Sc. Program: Students admitted in year ...